ANTI-INTERLEUKIN-17 MONOCLONAL ANTIBODY FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: RESULTS OF ANALYSIS OF A RUSSIAN PATIENT GROUP FROM THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MEASURE 1 AND MEASURE 2 TRIALS

ANTI-INTERLEUKIN-17 MONOCLONAL ANTIBODY FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: RESULTS OF ANALYSIS OF A RUSSIAN PATIENT GROUP FROM THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MEASURE 1 AND MEASURE 2 TRIALS

The article summarizes the data of two randomized controlled trials (RCTs) Phase III MEASURE 1 and MEASURE 2 investigating the efficacy and safety of secukinumab (SEC) in treating ankylosing spondylitis (AS) and compares the data with the results obtained from Russian patients with active AS, who we...

Full description

Bibliographic Details
Main Authors: Sh. F. Erdes, L. N. Denisov, A. L. Maslyansky, O. B. Ershova, M. L. Stanislav, T. S. Salnikova, N. V. Izmozherova, O. M. Lesnyak
Format: Article
Language:Russian
Published: IMA PRESS LLC 2017-03-01
Series:Научно-практическая ревматология
Subjects:
ankylosing spondylitis
secukinumab
measure 1 and measure 2 trials
efficacy
safety.
Online Access:https://rsp.mediar-press.net/rsp/article/view/2333

Internet

https://rsp.mediar-press.net/rsp/article/view/2333

Similar Items